The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences

• Main Authors: Minela Aida Maranduca (Author), Daniela Maria Tanase (Author), Cristian Tudor Cozma (Author), Nicoleta Dima (Author), Andreea Clim (Author), Alin Constantin Pinzariu (Author), Dragomir Nicolae Serban (Author), Ionela Lacramioara Serban (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.3390/pharmaceutics14091906; 1999-4923
• Keywords: renin-angiotensin-aldosterone system; RAAS; angiotensin-converting enzyme-2; ACE2; angiotensin 1-7; Ang (1-7); Pharmacy and materia medica; RS1-441
• Source: Pharmaceutics, Vol 14, Iss 9, p 1906 (2022)

The COVID-19 pandemic has put a tremendous stress on the medical community over the last two years. Managing the infection proved a lot more difficult after several research communities started to recognize the long-term effects of this disease. The cellular receptor for the virus was identified as angiotensin-converting enzyme-2 (ACE2), a molecule responsible for a wide array of processes, broadly variable amongst different organs. Angiotensin (Ang) 1-7 is the product of Ang II, a decaying reaction catalysed by ACE2. The effects observed after altering the level of ACE2 are essentially related to the variation of Ang 1-7. The renin-angiotensin-aldosterone system (RAAS) is comprised of two main branches, with ACE2 representing a crucial component of the protective part of the complex. The ACE2/Ang (1-7) axis is well represented in the testis, heart, brain, kidney, and intestine. Infection with the novel SARS-CoV-2 virus determines downregulation of ACE2 and interrupts the equilibrium between ACE and ACE2 in these organs. In this review, we highlight the link between the local effects of RAAS and the consequences of COVID-19 infection as they arise from observational studies.